In addition to immune checkpoint inhibitors covered above, there are also stimulatory checkpoint targets, such as OX40 (CD134) and 4-1BB (CD137), which can be activated to improve anti-tumor immunity. This evidence concerns the gene TNFRSF9 and neoplasm.